Dr Julie Simmonds
Equity Research Analyst, Healthcare
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in Life Sciences research, covering both UK and continental European companies across a wide range of Healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies.
Prior to Canaccord Genuity, Julie was a member of the No.1 Extel‑rated healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Lifesciences research.
Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
What does it take to be successful in a research role?
Being nosey! Asking lots of questions, reading around the science and really getting to understand the technologies which underpin the company and commercial potential is essential when covering the healthcare sector. The complex science then needs to be presented in a simple way, as much of the audience for our research does not have a scientific background. As many of our companies are pre-revenue and don’t have financials to interrogate, the underlying technology is essential.
What is the most fulfilling aspect about your work?
As an analyst focused on companies, l most enjoy when we’ve successfully raised money for one of our clients, particularly where we’ve needed to reposition the equity story first or educate investors on an area of healthcare which was poorly understood at the start. It is the first step in allowing companies to invest in creating products to help patients and ultimately to creating value for investors.
Where do you think are the greatest opportunities for Panmure Gordon moving forward?
In healthcare, the small to mid-cap growth companies remain poorly serviced by the investment banking community, with most of Panmure Gordon’s peers focused on the top 20% of the market. The opportunity to pick smaller companies and help them grow, through providing access to capital and good advice, differentiates us from peers. If we can increase corporate clients’ access into alternative pools of capital e.g. Europe/US/debt, then we can create more opportunities to help grow companies.